Off-label gebruik van bestaande en reeds goedgekeurde geneesmiddelen zoals liraglutide biedt voordelen omdat er al veel gegevens en ervaring beschikbaar zijn uit eerder onderzoek en praktisch gebruik

Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs

This helps to regulate blood sugar and digestion rate, which controls appetite & food cravings
Many medications can be taken alongside GLP-1 therapy, but interactions exist
You Have Difficulty Seeing If you have noticed a recent decline in your vision, there is a pretty good chance now is the time to consider vitamin B12 shots
Preparing for an ER Visit If you decide to go to the ER for stomach pain, preparation can help ensure a smoother experience